Cantillon Capital Management LLC Cuts Stake in Zoetis Inc. $ZTS

Key Points

• Cantillon Capital Management LLC reduced its stake in Zoetis Inc. by 2.8% in Q2, now holding approximately 1.22 million shares valued at about $190.1 million.
• Zoetis recently reported $1.76 EPS for the last quarter, surpassing estimates of $1.62, with a revenue of $2.46 billion, also above projections.
• The company announced a quarterly dividend of $0.50 per share, translating to an annualized yield of 1.4%, payable on December 2nd.

Cantillon Capital Management LLC lowered its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 2.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,219,095 shares of the company's stock after selling 35,370 shares during the period. Cantillon Capital Management LLC owned about 0.27% of Zoetis worth $190,118,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Nuveen LLC acquired a new stake in shares of Zoetis during the 1st quarter worth about $616,375,000. Mackenzie Financial Corp raised its holdings in Zoetis by 4,158.3% in the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock valued at $300,481,000 after buying an additional 1,782,110 shares during the period. Polen Capital Management LLC raised its holdings in Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after buying an additional 1,313,653 shares during the period. Amundi raised its stake in shares of Zoetis by 30.8% during the first quarter. Amundi now owns 3,595,628 shares of the company's stock valued at $575,691,000 after purchasing an additional 846,909 shares during the period. Finally, OVERSEA CHINESE BANKING Corp Ltd raised its stake in shares of Zoetis by 475.9% during the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company's stock valued at $148,228,000 after purchasing an additional 743,926 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Price Performance

NYSE ZTS opened at $146.13 on Wednesday. The stock's 50-day moving average price is $148.58 and its two-hundred day moving average price is $153.55. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The company has a market cap of $64.76 billion, a PE ratio of 25.15, a PEG ratio of 2.33 and a beta of 0.90. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $189.98.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis's payout ratio is 34.42%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research analyst reports. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. UBS Group reduced their price objective on shares of Zoetis from $165.00 to $158.00 and set a "neutral" rating for the company in a report on Monday. Finally, Argus reiterated a "buy" rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $195.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.